Nemours Children's Health System Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2009
NCT00915902
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Nemours Cardiac Center, Nemours Children's Hospital Delaware | Nemours Children's Clinic | Nemours Children's Health | Nemours Children's Health System | Samuel Gidding

Active Ingredients

Drugs in Phase 3 Trials (1)

icosapent ethyl (vascepa) (2 trials)

Drugs in Phase 2 Trials (1)

sulfur hexafluoride lipid-type a microspheres (Lumason) (1 trial)

Drugs in Other Trials (1)

l-glutamine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

Hypertriglyceridemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3